Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14332348 | 0.92 | MAPT (0.53) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL7067530 | 0.91 | ALOX15 (0.52) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL10895571 | 0.86 | ALDH1A1 (0.55) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL3438988 | 0.85 | MAPT (0.52) | MAPTALDH1A1TDP1L3MBTL1HPGD | |
| SCHEMBL10881492 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL10879742 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL10884052 | 0.84 | MAPT (0.49) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL11113053 | 0.84 | MAPT (0.49) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL10883853 | 0.82 | MAPT (0.48) | MAPTALDH1A1TDP1L3MBTL1MAPK1 | |
| SCHEMBL3439067 | 0.82 | TDP1 (0.46) | MAPTALDH1A1TDP1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MAPT 603/4885ALDH1A1 4403/4885TDP1 1065/4885 |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MAPT 603/4885ALDH1A1 4403/4885TDP1 1065/4885 |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | MAPT 603/4885ALDH1A1 4403/4885TDP1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.